Revenue of $5.3 billion increased 1.6% as reported, 0.4% FXN New BD revenue increased 2.5% FXN GAAP and adjusted diluted EPS of $1.34 and $2.91, respectively Combination of BD's Biosciences and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results